Introduction {#S0001}
============

Left ventricular systolic dysfunction (LVSD), measured as a reduction in left ventricular (LV) ejection fraction (LVEF), is prognostic of adverse outcomes, including all-cause mortality and heart failure (HF) in the general population.[@CIT0001] Nevertheless, LVEF has well-recognized limitations and LVSD may occur when LVEF is normal.[@CIT0002]

Speckle-tracking echocardiography (STE) is a comparatively new tool that quantifies myocardial mechanics,[@CIT0003] and may detect LVSD when LVEF is still preserved.[@CIT0002] Alterations in STE-derived LV strain are associated with risk factors for cardiovascular disease (CVD), including diabetes mellitus (DM),[@CIT0004] hypertension[@CIT0005] and obesity,[@CIT0006] and lower global longitudinal strain (GLS) predicts unfavorable outcomes in aortic stenosis, HF and hypertrophic cardiomyopathy.[@CIT0007]--[@CIT0010]

While systematic reviews and meta-analyses of STE-based LV strain as a predictor of adverse outcomes have previously been conducted based on studies of patients with established[@CIT0011],[@CIT0012] or established plus suspected CVD,[@CIT0013] a systemic review has not been performed for community-dwelling individuals, who were not selected on the basis of disease or clinical status. This is important, since selecting samples based on disease status can distort associations between risk factors and outcomes -- termed index event bias (collider bias).[@CIT0014] Also, community-dwelling individuals are at lower risk of CVD compared with selected diseased populations, and the utility of STE in this setting is uncertain but potentially of value.

We therefore conducted a systematic review and meta-analysis to examine whether STE is associated with risk of total and cardiovascular mortality and morbidity independent of conventional risk factors in community-dwelling individuals (ie, in the general population).

Materials and methods {#S0002}
=====================

This systematic review and meta-analysis was conducted according to a previously published protocol[@CIT0015] and conforms to the PRISMA guidance.[@CIT0016] The protocol was registered with the PROSPERO database (CRD42018090302).

Eligibility criteria {#S0002-S2001}
--------------------

All longitudinal studies (including placebo arms of population-based clinical trials) that assessed the prospective association of any STE-derived parameter with at least one of the pre-specified outcomes in community-dwelling individuals (\>18 years), who were not selected on the basis of disease or clinical status were eligible. Studies were included if they were reported in English, published in peer-reviewed journals and adhered to appropriate ethical standards. Abstracts, reviews, conference proceedings or letters to the editor were excluded.

Outcomes {#S0002-S2002}
--------

The primary outcome was all-cause mortality. Secondary outcomes were 1) a composite cardiac end-point, including any combination of cardiovascular mortality, coronary heart disease (CHD) events (myocardial infarction, unstable angina, angina/ischemia requiring emergent hospitalization or revascularization), HF hospitalization, new-onset atrial fibrillation (AF), life-threatening arrhythmia, recorded automatic implantable cardioverter defibrillator shocks, or 2) composite cardiovascular end-points, including a composite cardiac end-point and stroke, transient-ischemic attacks or peripheral arterial disease with arterial revascularization procedure. Any individual secondary end-points included in composite cardiac or cardiovascular end-points were considered as tertiary outcomes.

Search strategy {#S0002-S2003}
---------------

Literature was searched in MEDLINE and EMBASE via OvidSP interface. Search strategies are shown in the [[Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul} and data to be extracted were predefined.[@CIT0015] The last search was carried out on February 28, 2018. Additional papers could be identified by searching the reference lists of relevant articles and their citation metrics using Web of Science Core Collection.

Study selection and data extraction {#S0002-S2004}
-----------------------------------

Search results from each database were combined and duplicates were removed before screening. Initial title and abstract screening were performed and full texts of selected articles were retrieved and double screened for eligibility using a predefined eligibility form,[@CIT0015] and data extracted using a predefined form.[@CIT0015] Screening and extraction was performed by two researchers working independently (L.A. and C.P.). Discrepancies were reviewed and resolved through consensus.

Quality assessment {#S0002-S2005}
------------------

A modified version of the Newcastle-Ottawa Quality Assessment Scale of cohort studies[@CIT0017] was used to assess the quality of included papers.[@CIT0015] The total quality score was reported as the average of the two researchers' scores ranging from 0 (lowest quality score) to 7 (highest quality score). Papers were included irrespective of the quality assessment score.

Statistical methods {#S0002-S2006}
-------------------

All analyses were performed using Stata 15.1 (StataCorp LLC, USA). We used random effects meta-analysis to pool effect estimates and calculated the 95% CIs of the relevant HRs based on the expectation of heterogeneity between different studies. All HRs were rescaled to per unit strain (%). Results were presented graphically as forest plots and heterogeneity was assessed using Higgins Thompson I^2^ test and Cochran's Q test.[@CIT0015]

We planned to carry out a meta-analysis on a minimally adjusted model (ie, age, sex and ethnicity \[if relevant\]) and a maximally adjusted model, including cardiovascular risk factors and conventional echocardiographic measures. Meta-analyses were only possible for GLS. Endocardial strain was used for primary analyses, but we performed sensitivity analysis by repeating analyses replacing endocardial with midwall or epicardial strains when available.

We planned to assess potential sources of heterogeneity,[@CIT0015] but were unable to perform any subgroup analysis or meta-regression due to the limited number of identified studies per analysis. Similarly, it proved impossible to compare different software for STE analysis due to lack of relevant data.

Results {#S0003}
=======

Search results and study selection {#S0003-S2001}
----------------------------------

A PRISMA diagram is shown in [Figure 1](#F0001){ref-type="fig"}. A total of 7040 records were identified. After removing duplicates, 6222 records of 6235 were excluded by title and abstract. Thirteen full text articles were assessed for eligibility. Five did not meet the inclusion criteria (n=1: ineligible outcome[@CIT0018] n=4: same cohort, deemed not population representative due to selection criteria[@CIT0019]--[@CIT0022]), the other eight papers from five studies were eligible (n=2 from Cardiovascular Abnormalities and Brain Lesion study,[@CIT0023],[@CIT0024] n=3 from Copenhagen City Heart Study[@CIT0025]--[@CIT0027], and n=1 from Framingham Offspring Study and Framingham Omni Study,[@CIT0028] Flemish Study on Environment, Genes and Health Outcomes \[FLEMENGHO[@CIT0029] and Atherosclerosis Risk in Communities [@CIT0030]).Figure 1PRISMA flow diagram illustrates different stages of this systematic review.

Characteristics of included papers {#S0003-S2002}
----------------------------------

Characteristics of included papers are shown in [Table 1](#T0001){ref-type="table"} (additional information regarding the studies is included in [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul}). Most (4/8) were based on US samples (two papers from the same study).[@CIT0023],[@CIT0024],[@CIT0028],[@CIT0030] The remainder included one paper from Belgium[@CIT0029] and three papers (from the same study) from Denmark.[@CIT0025]--[@CIT0027] The total number of participants was 11,744, participants in the five studies reported in the eight identified papers ranged between 675 and 6118. Follow-up ranged between 608 days (469--761) (median; IQR)[@CIT0030] and 12.5 years (9.4--12.8).[@CIT0027] One study recruited participants free of CVD at baseline,[@CIT0028] while others included participants with known CVD.Table 1Brief characteristics of included studiesReferenceStudy nameStudy designRegionnAge (years)Female (%)EthnicityF/UHTN (%)DM (%)Dyslipidemia (%)Smoking status (%)Known CVD (%)^\*^Russo et al (2014)[@CIT0023]Cardiovascular Abnormalities and Brain Lesion (CABL) studyLongitudinal (cohort) studyManhattan, USA70871±9431 (61)66.8% Hispanics, 17.1% blacks, 14.1% whites, and 2% of other race-ethnicities.4.8±1.5 years\
(0.06, 7.38)548 (77.4)197 (27.8)Hypercholesterolemia: 462 (65.2)Smoking history: 374 (53)CAD: 36 (5.08)\
AF: 41 (5.79Cheng et al (2015)[@CIT0028]The Framingham Offspring Study and the Framingham Omni StudyFramingham, Massachusetts, USA283166±91613 (57)259 (9) non-white ethnicity6.0±1.2 years1679 (59)365 (13)N/ACurrent smoker: 236 (8)0^\*^Russo et al (2015)[@CIT0024]CABL studyManhattan, USA67571±9408 (60)N/A63.6±18.7 months521 (77)187 (27.7)Hypercholesterolemia: 443 (65.6)N/ACAD: 39 (5.7)\
Hx HF: 19 (2.8)Kuznetsova et al (2016)[@CIT0029]Flemish Study on Environment, Genes and Health Outcomes (FLEMENGHO)Northern Belgium79150.8±15.5410 (51.8)White EuropeansMedian (5^th^--95^th^ percentile): 7.9 years (3.7--9.6)326 (41.2)34 (4.3)N/ACurrent smokers: 167 (21.1)43 (5.4)^†^Biering-Sorensen et al (2017)[@CIT0025]Copenhagen City Heart StudyCopenhagen, Denmark129657.0±16.2747 (57.6)Almost all whiteMedian (IQR): 11.0 years (9.9--11.2)489 (37.8)122 (9.4)N/ANever: 428 (33.3)\
Previous: 426 (33.2)\
Current: 430 (33.5)Previous IHD: 64 (4.9)^†^Brainin et al (2018)[@CIT0026]Copenhagen City Heart StudyCopenhagen, Denmark129656.9±16.2747 (57.6)Almost all whiteMedian (IQR): 11.0 years (9.9--11.2)489 (37.7)122 (9.4)186 (14.3)Never: 380 (29.3)\
Previous: 394 (30.4)\
Current: 401 (30.9)Previous IHD: 64 (4.9)^†^Modin et al (2018)[@CIT0027]Copenhagen City Heart StudyCopenhagen, Denmark129457.0±16.2744 (57.5)N/AMedian (IQR): 12.5 years (9.4--12.8)489 (38.3)123 (9.5)N/A406 (33.4)IHD: 63 (4.9)\
Ischemic stroke: 25 (1.9)Shah et al (2017)[@CIT0030]Atherosclerosis Risk in Communities (ARIC)USA6118Median (IQR): 75.3 (71.7, 79.7)3548 (58)22% blackMedian (IQR): 608 days (469--761)5078 (83)2325 (38)N/AEver: 3793 (62)\
Current smoker: 367 (6)CAD: 1040 (17)\
MI: 489 (8)\
PAD: 367 (6)\
Stroke: 245 (4)\
AF: 428 (7)[^1][^2]

Exposures and outcomes of included papers {#S0003-S2003}
-----------------------------------------

Exposures and outcomes from included papers are shown in [Table 2](#T0002){ref-type="table"}. All used two-dimensional speckle-tracking echocardiography (2D-STE). Two used Philips QLAB 8.1, two used TomTec CPA and four used EchoPac. All studies (n=8) assessed GLS. One study also assessed circumferential, radial and transverse strains[@CIT0028] and another assessed GLS-derived post-systolic shortening measures.[@CIT0026] None assessed LV rotational measures in association with the chosen outcomes. All papers except one[@CIT0027] provided data on exposure reliability (intra-observer,[@CIT0029],[@CIT0030] inter-observer[@CIT0024] reproducibility or both[@CIT0023],[@CIT0025],[@CIT0026],[@CIT0028]).Table 2Exposure and outcome characteristics of the included papersExposure characteristicsOutcome characteristicsReferences**HardwareSoftwareProcedureMeasured parameterImages obtained fromNumber of segments involved**Number of sonographers perform the analysisProvided data on exposure reliabilityPrimary outcomeSecondary outcomesTertiary outcomes(All- cause mortality)Composite CV end pointComposite\
cardiac end pointRusso et al (2014)[@CIT0023]E 33, PhilipsPhilips QLAB 8.12D-STELongitudinal strainApical 4- and 2-chamber views12 segmentsN/AIntra-observer reproducibility:\
ICC 0.82 (95% CI; 0.60--0.93, \<0.01), mean difference (0.07±2.3%), and COV (SD/mean) 8.4%.\
Inter-observer reproducibility:\
ICC 0.85, mean difference (0.08±2.4%) and COV 9.2%.n=58\
(included ischemic stroke \[n=16\], MI \[n=10\], and vascular death \[n=32\])Cheng et al (2015)[@CIT0028]Hewlett-Packard 5500, PhilipsCardiac Performance Analysis \[CPA\] v1.1; TomTec Imaging Systems2D-STE1. Longitudinal strainApical 4- and 2-chamber viewsN/A2. Circumferential strainMid-ventricular parasternal short-axisN/A3. Radial strainMid-ventricular parasternal short axisN/A4. Transvers strainApical 4- and 2- chamber viewsN/A1 sonographer per specific viewIntra-observer reproducibility:\
Average COV:\
\<6% for global longitudinal and circumferential strain.\
\<9% for global transvers and radial strain.\
Inter-observer reproducibility:\
Average COV:\
≤4% for global longitudinal and circumferential strain.\
\<8% for global transvers and radial strain.n=199\
14= CHD, 8= cerebrovascular disease, and 13= other CVD causes.\
164 death not attributable to a CVD cause.New-onset CHD: n=69\
(comprising fatal or nonfatal MI, coronary insufficiency, and angina pectoris)New-onset CHD:\
n=69\
(comprising fatal or nonfatal MI, coronary insufficiency, and angina pectoris)\
HF: n=71Russo et al (2015)[@CIT0024]iE 33, PhilipsPhilips QLAB 8.12D-STELongitudinal strainApical 4- and 2-chamber views12 segmentsN/AInter-observer reproducibility:\
ICC 0.85, mean difference (0.08±2.4%), and COV 0.09.AF: n=32Kuznetsova et al (2016)[@CIT0029]Vivid7 Pro, GEEchoPac, BT113, GE2D-STELongitudinal strainApical 4-chamber viewN/A1Intra-observer reproducibility:\
Absolute bias 0.47±0.55% and absolute limit of agreement ranged from 0.62% to 1.55% (reproducibility =1.1%).\
Relative bias −2.51±3.02% and the limits of agreement ranged from 8.44% to 3.41% (reproducibility=6.1%).n=96\
(comprised cardiac end-points, stroke, transient ischemic attack, aortic aneurysm, arterial embolism, and revascularization of peripheral arteries)n=68\
(Included coronary events, fatal and nonfatal HF, pulmonary heart disease, new-onset AF, and life-threatening arrhythmias)Coronary events:\
n=34 \[included fatal and nonfatal MI, coronary revascularization, and new-onset angina (stable or unstable)\]Biering-Sorensen et al (2017)[@CIT0025]Vivid 5, GEEchoPac, 2008, GE2D-STELongitudinal strainApical 4-, 3- and 2-chamber views when possibleN/A1Intra-observer reproducibility:\
Mean difference ±1.96 SD (0.1±1.6%).\
Inter-observer reproducibility:\
Mean difference ±1.96 SD (−0.08±2.0%).n=149\
(comprising AMI \[n=43\], HF \[n=78\], and CV death \[n=74\])AMI: n=43 (3.3%)\
HF: n=78 (6.0%)\
CV death: n=74 (5.7%)Brainin et al (2018)[@CIT0026]Vivid 5, GEEchoPac, 2008, GE2D-STELongitudinal strainPost-systolic index, post-systolic strain, peak post-systolic time and, post-systolic shorteningApical 4-, 3- and 2-chamber views when possible18 (6 per view)1Intra-observer reproducibility:\
PSS: mean difference ±1.96 SD (0.2±0.95)\
PSI: mean difference ±1.96 SD (0.25±0.74)\
Inter-observer reproducibility:\
PSS: mean difference ±1.96 SD (−0.04±0.73)\
PSI: mean difference ±1.96 SD (0.06±0.56)n=236 (18.1%)n=149 (11.5%)\
(composite of HF \[n=78\], MI \[n=43\], and CV death \[n=74\])Modin et al (2018)[@CIT0027]Vivid 5, GEEchoPac, 2008, GE2D-STELongitudinal strainApical 4-, 3- and 2-chamber views when possibleGLS was calculated as the average of strain values from available viewsN/ANon=222 (17.2%)\
(Composite outcome of either IHD or HF)\
n=145 (65%) in hypertensive participants\
and n=77 (35%) in non-hypertensive individualsShah et al (2017)[@CIT0030]iE 33, PhilipsTomTec CPA package2D-STELongitudinal strainApical 4- and 2-chamber views6 in each viewMultiple (4)Intra-observer reproducibility:\
Mean difference±SD (0.2±1.4% for LS in apical 4 chamber view; and 0.8±1.2% in apical 2-chamber view) and COV 7.7% for LS in apical 4-chamber view and 6.4% in apical 2-chamber view.n=194\
(composite of deaths \[n=145\] and HF \[n=113\])[^3]

GLS and all-cause mortality {#S0003-S2004}
---------------------------

Two studies found associations between 2D-STE-derived measures and all-cause mortality [Table (3)](#T0003){ref-type="table"}.[@CIT0026],[@CIT0028] GLS was reported in both studies; however, only one[@CIT0028] provided both minimally and maximally adjusted estimates. Consequently, meta-analysis was only performed on the two minimally adjusted estimates; pooled HR=1.07 (1.03--1.11), *p*=0.001 ([Figure 2A](#F0002){ref-type="fig"}).Figure 2GLS as a predictor of all-cause mortality (**A**), composite cardiac end-point (**B**) and cardiovascular end-point (**C**). All-cause mortality HR estimates are from minimally adjusted (Cheng et al) and unadjusted (Brainin et al) models. Composite cardiovascular and cardiac end-points are based on maximally adjusted models (listed in the [[Supplementary materials](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul}). For Kuznetsova et al, endocardial-wall strain is shown. Hazard ratios are per unit change in strain value. The heterogeneity assessment including the I^2^ statistics and *p*-value of Q test is shown.

GLS and composite cardiovascular end-point {#S0003-S2005}
------------------------------------------

Two studies reported associations between GLS and a composite cardiovascular end-point, but neither provided a minimally adjusted estimate ([Table 3](#T0003){ref-type="table"}).[@CIT0023],[@CIT0029] Random effect meta-analysis indicated that lower 2D-STE-based GLS was associated with higher risk of a composite cardiovascular end-point; pooled maximally adjusted HR=1.18 (1.09--1.28), *p*\<0.0001 ([Figure 2C](#F0002){ref-type="fig"}). Substituting mid-wall or epicardial-wall strains for endocardial strain did not alter this finding ([[Figure S1](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul}).

GLS and composite cardiac end-point {#S0003-S2006}
-----------------------------------

Among six papers which assessed different 2D-STE-derived measures,[@CIT0025]--[@CIT0030] only GLS or a GLS-derived measure (post-systolic index) was associated with a composite cardiac end-point ([Table 3](#T0003){ref-type="table"}). Three of these papers were from the same study population;[@CIT0025]--[@CIT0027] one study was not suitable for quantitative synthesis because the estimates provided combined GLS and LVEF, and were available only for a selected high-risk subset of the population (stage A and B HF)[@CIT0030] therefore, data from three papers[@CIT0025],[@CIT0028],[@CIT0029] were used for meta-analysis. Low GLS predicted higher HR of a composite cardiac end-point; pooled maximally adjusted HR=1.08 (1.02--1.14), *p*=0.006 ([Figure 2B](#F0002){ref-type="fig"}). A sensitivity analysis showed that replacing the endocardial with mid- or epicardial-wall strains[@CIT0029] had minimal effect ([[Figure S3](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul}). Analysis of minimally adjusted estimates is shown in [[Figure S2](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul}.Table 3Results of studies assessed the association between two-dimensional speckle-tracking echocardiographic-derived measures and all-cause mortality, composite cardiovascular and cardiac end-pointsCitationExposurePrimary outcomeSecondary outcomesUnitAll- cause mortalityComposite CV end pointComposite cardiac end pointHRs, 95% CI, Pn (events)\
Adjustments,HRs, 95% CI, Pn (events)\
Adjustments,HRs, 95% CI, Pn (events)\
Adjustments,**Russo et al (2014)**[@CIT0023]Global longitudinal strain (GLS)N/AN/An = 58N/AN/APer unit decrease1.24 (1.12, 1.37), \<0.001None1.15 (1.03, 1.28), 0.012Age, sex, SBP, DBP, HTN, anti-hypertensive medications, DM, LVMi, relative wall thickness, LAVi, diastolic dysfunction, and AF (Model 1)1.15 (1.03, 1.28), 0.012Model 1+ LVEF**Cheng et al, (2015)**[@CIT0028]Global average longitudinal strainn = 199N/AN/An = 69Per 1 SD change (SD=3.3%)1.31 (1.14, 1.52), 0.0002Age, sex and ethnicity (Model 1)1.37 (1.06, 1.76), 0.01Model 11.24 (1.05, 1.46), 0.01Age, sex, ethnicity, BMI, SBP, DBP, anti-hypertensive treatment, total/HDL cholesterol, DM, smoking status, and HR (Model 2)1.36 (1.03, 1.79), 0.03Model 21.21 (1.02, 1.44), 0.03age, sex, ethnicity, BMI, SBP, DBP, anti-hypertensive treatment, total/ HDL cholesterol, DM, smoking status, LV mass, LV fractional shortening, and HR (Model 3)1.29 (0.96, 1.74), 0.09Model 3Global average circumferential strain1.3 (1.12, 1.52), 0.0007Model 11.1 (0.85, 1.42), 0.48Model 1Per 1 SD change (SD=5.8%)1.21 (1.04, 1.42), 0.02Model 21.14 (0.87, 1.48), 0.34Model 21.11 (0.92, 1.34), 0.27Model 31.11 (0.81, 1.51), 0.53Model 3Global average radial strain0.73 (0.61, 0.87), 0.0003Model 10.87 (0.67, 1.13), 0.3Model 1Per 1 SD change (SD=16.8%)0.76 (0.64, 0.91), 0.002Model 20.9 (0.68, 1.17), 0.43Model 20.82 (0.68, 0.98), 0.03Model 30.95 (0.72, 1.26), 0.72Model 3Global average transvers strain0.93 (0.81, 1.07), 0.32Model 11.02 (0.80, 1.29), 0.89Model 1Per 1 SD change (SD=7.1%)0.99 (0.85, 1.14), 0.85Model 21.02 (0.81, 1.29), 0.87Model 21 (0.85, 1.17), 0.97Model 31.04 (0.81, 1.34), 0.75Model 3**Kuznetsova et al (2016)**[@CIT0029]GLSn =96n = 68Mid-wallN/AN/A1.75 (1.39, 2.20), \<0.0001Clinical model = Family clusters, sex, age, BMI, SBP, serum cholesterol, smoking, antihypertensive treatment, DM, and a history of cardiac disease.1.54 (1.21, 1.96), 0.0005Clinical modelPer 1 SD decrease\
(SD= 2.5%)1.75 (1.36, 2.20), \<0.0001Clinical model + LVMi1.54 (1.21, 2.0), 0.0005Clinical model + LVMi1.61 (1.27, 2.08), \<0.0001Clinical model + TDI e′1.45 (1.13, 1.85), 0.0045Clinical model + TDI e′1.61 (1.27, 2.08), \<0.0001Clinical model + LVMI + TDI e′1.45 (1.13, 1.89), 0.0041Clinical model + LVMI + TDI e′EndocardialN/AN/A1.74 (1.35, 2.19), \<0.0001Clinical model1.54 (1.22, 1.95), 0.0005Clinical modelPer 1 SD decrease (SD= 2.9%)1.7 (1.35, 2.14), \<0.0001Clinical model + LVMi1.54 (1.22, 1.95), 0.0005Clinical model + LVMi1.62 (1.25, 2.05), \<0.0001Clinical model + TDI e′1.43 (1.12, 1.87), 0.0043Clinical model + TDI e′1.62 (1.25, 2.05), 0.0001Clinical model + LVMI + TDI e′1.46 (1.12, 1.87), 0.0041Clinical model + LVMI + TDI e′EpicardialN/AN/A1.66 (1.33, 2.10), \<0.0001Clinical model1.49 (1.18, 1.90), 0.001Clinical modelPer 1 SD decrease (SD= 2.2%)1.66 (1.31, 2.10), \<0.0001Clinical model + LVMi1.49 (1.18, 1.90), 0.001Clinical model + LVMi1.55 (1.23, 1.97), 0.0002Clinical model + TDI e′1.41 (1.10, 1.81), 0.0067Clinical model + TDI e′1.55 (1.23, 1.97), 0.0002Clinical model + LVMI + TDI e′1.41 (1.11, 1.81), 0.0062Clinical model + LVMI + TDI e′**Biering-Sorensen et al (2017)**[@CIT0025]GLSN/AN/AN/AN/An = 1491.12 (1.08, 1.17), \<0.001NonePer unit (1%) decrease1.08 (1.04, 1.13), \<0.001Age and sex1.07 (1.01, 1.11), 0.013Clinical model = Age, sex, HR, HTN, DM, previous ischemic heart disease, SBP, and pro-BNP (\>150 pmol/L)1.05 (1.0, 1.11), 0.045Clinical model + LVEF(\<50%), LVMi, LV dimension, deceleration time, LA dimension, and E/e′**Brainin et al (2018)**[@CIT0026]n = 236N/AN/An = 149GLS1.05 (1.02, 1.09), 0.004None1.12 (1.08, 1.17), \<0.001NonePer unit (1%) decreasePost systolic index1.33 (1.21, 1.47), \<0.001None1.36 (1.20, 1.54), \<0.001NonePer 1% increase1.14 (1.0, 1.30), 0.044Age, sex, HTN, HR, LVMi, LVEF, GLS, pro-B-type natriuretic peptide, previous ischemic heart disease, SBP, LAVi, e', estimated glomerular filtration rate, and E/A1.22 (1.04, 1.43), 0.014Age, sex, HTN, HR, LVMi, LVEF, GLS, pro-B-type natriuretic peptide, previous ischemic heart disease, SBP, LAVi, e', estimated glomerular filtration rate, and E/A**Modin et al (2018)**[@CIT0027]GLSN/AN/AN/AN/An = 2221.67 (1.41, 1.99), \<0.001NonePer 5% decrease1.37 (1.14, 1.65), 0.001Clinical model = Age, sex, SBP, smoking status, DM and total cholesterol and HTN1.23 (0.99, 1.52), 0.06Clinical model + GLS, LVMi, LAVi, LVIDd/height, HR, E/e′, a′, prevalent IHD, and abnormal ECG.**Shah et al (2017)**[@CIT0030]GLSN/AN/AN/AN/AResults were not used for meta-analysis as GLS and LVEF were combined into a composite measure and used as a surrogate of LV systolic dysfunction[^4]

GLS and tertiary outcomes {#S0003-S2007}
-------------------------

Four papers provided data on GLS in association with tertiary outcomes,[@CIT0024],[@CIT0025],[@CIT0028],[@CIT0029] one of which assessed circumferential, radial and transverse strains[@CIT0028] ([Table 4](#T0004){ref-type="table"}). Three papers reported CHD,[@CIT0025],[@CIT0028],[@CIT0029] two HF,[@CIT0025],[@CIT0028] one AF[@CIT0024] and one cardiovascular death.[@CIT0025] GLS was associated with CHD, AF and HF, whereas circumferential strain was only associated with HF although this was assessed in only one study ([Table 4](#T0004){ref-type="table"}). Meta-analysis showed that GLS was a predictor of CHD and HF (CHD maximally adjusted HR=1.15 \[1.03--1.29\], *p*=0.017; HF HR=1.07 \[1.01--1.13\]*, p*=0.012; [Figure 3](#F0003){ref-type="fig"}). Meta-analysis based on minimally adjusted estimates is shown in [[Figure S4](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul}, and further sensitivity analysis was performed for CHD replacing the endocardial with mid- or epicardial-wall strains and results were hardly altered ([[Figure S5](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul}). Additional information from studies that reported Kaplan--Meier data related to various outcomes is shown in [[Table S1](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul}.Table 4Results of studies assessed the association between two-dimensional speckle-tracking echocardiographic-derived measures and tertiary outcomesReferencesTertiary outcomes (n)ExposureResultsUnitHRs, 95% CI, PAdjustments**Cheng et al (2015)[@CIT0028]**1. Coronary heart disease (69) (comprising fatal or nonfatal myocardial infarction, coronary insufficiency, and angina pectoris)Global average longitudinal strain1.37 (1.06, 1.76), 0.01Age, sex and ethnicity (Model 1)Per 1 SD change (SD=3.3%)1.36 (1.03, 1.79), 0.03Age, sex, ethnicity, BMI, SBP, DBP, anti-hypertensive treatment, total/HDL cholesterol, DM, smoking status, and HR (Model 2)1.29 (0.96, 1.74), 0.09age, sex, ethnicity, BMI, SBP, DBP, anti-hypertensive treatment, total/ HDL cholesterol, DM, smoking status, LV mass, LV fractional shortening, and HR (Model 3)Global average circumferential strain1.1 (0.85, 1.42), 0.48Model 1Per 1 SD change (SD=5.8%)1.14 (0.87, 1.48), 0.34Model 21.11 (0.81, 1.51), 0.53Model 3Global average radial strain0.87 (0.67, 1.13), 0.3Model 1Per 1 SD change (SD=16.8%)0.9 (0.68, 1.17), 0.43Model 20.95 (0.72, 1.26), 0.72Model 3Global average transvers strain1.02 (0.80, 1.29), 0.89Model 1Per 1 SD change (SD=7.1%)1.02 (0.81, 1.29), 0.87Model 21.04 (0.81, 1.34), 0.75Model 32. Heart failure (71)Global average longitudinal strain1.45 (1.14, 1.84), 0.003Model 1Per 1 SD change (SD=3.3%)1.29 (0.99, 1.69), 0.06Model 21.14 (0.86, 1.50), 0.37Model 3Global average circumferential strain1.7 (1.29, 2.25), 0.0002Model 1Per 1 SD change (SD=5.8%)1.59 (1.18, 2.14), 0.002Model 21.41 (1.0, 2.0), 0.05Model 3Global average radial strain0.64 (0.46, 0.88), 0.007Model 1Per 1 SD change (SD=16.8%)0.82 (0.59, 1.13), 0.22Model 20.98 (0.72, 1.34), 0.92Model 3Global average transvers strain0.73 (0.57, 0.93), 0.01Model 1Per 1 SD change (SD=7.1%)0.79 (0.61, 1.02), 0.07Model 20.84 (0.65, 1.1), 0.21Model 3**Russo et al, (2015)**[@CIT0024]Atrial fibrillation (32)Global average longitudinal strain1.2 (1.08, 1.34), 0.001NonePer unit (1%) decrease\
Death as a Competing Risk\
1.22 (1.04, 1.43), 0.015\
Age, obesity, HTN, antihypertensive treatment, coronary artery disease, LVMi, relative wall thickness.**Kuznetsova et al (2016)**[@CIT0029]Coronary heart disease (34)\
Comprising fatal and nonfatal myocardial infarction, coronary revascularization, and new-onset angina (stable or unstable).Global longitudinal strainMid-wall2.45 (1.61, 3.66), \<0.0001Clinical model = Family clusters, sex, age, BMI, SBP, serum cholesterol, smoking, antihypertensive treatment, DM, and a history of cardiac disease.Per 1 SD decrease (SD= 2.5%)2.53 (1.68, 3.82), \<0.0001Clinical model + LVMi2.32 (1.51, 3.55), \<0.0001Clinical model + TDI e′2.4 (1.54, 3.71), \<0.0001Clinical model + LVMI + TDI e′ Endocardial 2.34 (1.58, 3.50), \<0.0001Clinical modelPer 1 SD decrease (SD= 2.9%)2.44 (1.62, 3.77), \<0.0001Clinical model + LVMi2.24 (1.46, 3.43), 0.0002Clinical model + TDI e′2.29 (1.50, 3.56), 0.0002Clinical model + LVMI + TDI e′Epicardial2.3 (1.58, 3.38), \<0.0001Clinical modelPer 1 SD decrease (SD= 2.2%)2.4 (1.61, 3.56), \<0.0001Clinical model + LVMi2.2 (1.47, 3.30), \<0.0001Clinical model + TDI e′2.26 (1.49, 3.38), \<0.0001Clinical model + LVMI + TDI e′**Biering-Sorensen et al (2017)**[@CIT0025]1. Heart failure (78)Global longitudinal strain1.16 (1.09, 1.23), \<0.001NonePer unit (1%) decrease1.12 (1.05, 1.18), \<0.001Age and sex (Model 1)1.1 (1.03, 1.17), 0.003Age, sex, HR, HTN, DM, previous IHD, SBP, and pro-BNP (\>150 pmol/L) (Model 2)1.09 (1.02, 1.17), 0.016Age, sex, HR, HTN, DM, previous IHD, SBP, pro-BNP (\>150 pmol/L), LVEF(\<50%), LVMi, LV dimension, deceleration time, LA dimension, and E/e′ (Model 3)2. Acute myocardial infarction (43)1.16 (1.08, 1.26), \<0.001NonePer unit (1%) decrease1.13 (1.04, 1.22), 0.003Model 11.1 (1.01, 1.19), 0.022Model 21.11 (1.01, 1.22), 0.024Model 33. Cardiovascular death (74)1.06 (1.0, 1.13), 0.059NonePer unit (1%) decrease1.02 (0.96, 1.08), 0.54Model 10.99 (0.93, 1.06), 0.85Model 20.98 (0.91, 1.06), 0.59Model 3[^5] Figure 3GLS as a predictor of coronary heart disease (**A**) and heart failure (**B**) on maximally adjusted models (listed in the [[Supplementary materials]{.ul}](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)). For Kuznetsova et al, endocardial-strain is shown. Hazard ratios are per unit change in strain value. The heterogeneity assessment including the I^2^ statistics and *p*-value of Q test is shown.

Publication bias and study quality {#S0003-S2008}
----------------------------------

Assessment of publication bias was not possible due to the small number of identified studies. The quality of the studies was good. Seven scored a maximum 7[@CIT0023]--[@CIT0026],[@CIT0028]--[@CIT0030] and one scored 6[@CIT0027] ([[Table S2](https://www.dovepress.com/get_supplementary_file.php?f=206747.pdf)]{.ul}). The degree of heterogeneity indicated by I-square was small in most of the meta-analyses and was only large in two analyses.

Discussion {#S0004}
==========

This systematic review and meta-analysis summarizes current evidence about the prognostic value of STE-derived measures in the general population. 2D-STE-derived GLS was the most studied measure and it predicted total mortality, major adverse cardiac and cardiovascular end-points in community-dwelling individuals in a limited number of studies that included a total of 11,744 participants. Although information on potential confounders was limited and inconsistent, there was some evidence that this was independent of conventional cardiovascular risk factors and other echocardiographic measures. There was insufficient evidence in relation to other myocardial deformation indices or 3D-STE-derived indices to draw conclusions with respect to outcomes. Therefore, this systematic review also highlights important knowledge gaps in the current literature regarding the possible utility of myocardial deformation indices in unselected older populations, and further evidence is still required, particularly regarding 3D-STE.

Risk assessment and management of patients with CVD are guided by the measurement of LV global systolic function.[@CIT0002] LVEF is considered the cornerstone in assessing LV systolic function,[@CIT0001] but LV strain imaging is attracting interest as an additional tool to improve risk assessment and guide management in diseased populations.[@CIT0002],[@CIT0012] Nevertheless, the evidence on the utility of STE as a measure of cardiac function and risk in community-dwelling individuals has been limited. We provide a synthesis of current evidence that provides some support for GLS as a useful risk measure but also highlights the need for more information regarding the utility of STE for risk assessment and diagnosis. Based on limited numbers of identified studies, GLS was a prognostic marker of cardiovascular mortality and morbidity independent of conventional risk factors. This is important because risk factors which potentially lead to CVDs such as aging, hypertension and DM are common characteristics of longitudinal population-based samples of elderly[@CIT0023]--[@CIT0030] and are known to be associated with alterations in GLS even when LVEF is still normal.[@CIT0004],[@CIT0005],[@CIT0031],[@CIT0032]

According to the disease progression, the layers of the myocardium as well as the various other contributors to cardiac mechanics can be affected differently.[@CIT0033] Disease affecting the subendocardial layer such as ischemia, hypertension or DM tends to impair longitudinal mechanics, while circumferential and twist mechanics remain preserved or even enhanced to preserve the overall LV systolic performance and LVEF.[@CIT0033],[@CIT0034] With more involvement of the mid-myocardial and subepicardial layers, both circumferential and twist mechanics will deteriorate leading to a reduction in LVEF.[@CIT0003],[@CIT0033] In unselected population without overt cardiac diseases, Russo et al characterized the relationship between multidirectional myocardial mechanics with radial thickening and LVEF.[@CIT0035] Radial strain was more influenced by circumferential strain than longitudinal strain explaining why radial thickening, and hence LVEF, is less sensitive than longitudinal function in detecting subclinical LVSD.[@CIT0035] This may contribute to the added prognostic value of GLS over LVEF especially when LVEF is still normal or mildly impaired.[@CIT0012]

STE-based LV strain imaging allows comprehensive quantification of complex myocardial mechanics. While STE is increasingly used in clinical practice, it suffers from inherent technical limitations.[@CIT0031] High-quality images and adequate frame rates are crucial for accurate tracking. For 2D-STE, multiple views are required which is time-consuming to apply in large population-based studies. Indeed, among identified studies,[@CIT0023]--[@CIT0030] only one study measured circumferential, radial and transverse strains,[@CIT0028] while none measured LV rotation.[@CIT0026] This could be due to analysis time required or the limited feasibility and reproducibility of these measurements. Nevertheless, circumferential strain, both MRI-based[@CIT0036] and 2D-STE based,[@CIT0028] was an independent prognostic marker for incident HF over and beyond traditional risk factors and conventional measures in subjects free of CVDs of community-dwelling individuals. Further, Cheng et al have suggested that distinct components of LV mechanics (ie, GLS, circumferential strain, etc.) are differently associated with individual CVD outcomes,[@CIT0028] but it was not possible to answer this question due to the limited number of studies. In the future, 3D imaging methods may overcome some of the limitations of 2D-STE and provide additional insight to the different relationship between individual components of LV mechanics and CVD outcomes.

Study limitations {#S0005}
=================

A number of limitations of this study ought to be acknowledged. This systematic review was limited to English language publications, which may have introduced a selection bias. We identified only eight papers based on five different studies; all identified studies used 2D-STE and no study examined additive the prognostic value of 3D-STE-derived LV deformation indices in a general population. Once multiple publications from the same study were accounted for, meta-analyses were based on either two or three studies limiting the precision of estimates of between-study variance which could result in an underestimate of the width of the confidence intervals. Further, meta-analysis should be performed when results of at least ten relevant studies are available. The small number of studies also precluded sub-group analysis and meta-regression to explore sources of heterogeneity between studies. We assumed a priori that there would be heterogeneity between the various observational studies and consequently used random effects modeling, although there was not strong evidence of heterogeneity in the identified studies. Since estimates from random effects models behave like the fixed effect estimate as heterogeneity decreases, it is not likely that this will have introduced substantial error. The small number of studies also prevented us from employing formal assessment of publication bias (e.g. funnel plots), but this bias cannot be excluded. Analyses employed different vendor-specific software and possibly different software versions; both are factors which may introduce systematic differences between studies. For this reason, GLS analysis including LV segmentation is different between studies included in this meta-analysis (e.g. endocardial analysis of GLS from 12 LV-segments,[@CIT0028] transmural analysis of GLS from 18 LV-segments[@CIT0025] or GLS from only 6 LV-segments[@CIT0029]). However, since we examined associations with outcomes in relation to a continuous exposure (GLS) the impact of this source of heterogeneity is likely to be small, consistent with our sensitivity analysis.

Conclusion {#S0006}
==========

This study synthesized current evidence regarding STE-derived measures as prognostic indicators of mortality and cardiovascular events in community-dwelling individuals. Despite limited number of studies in this meta-analysis, LV GLS by 2D-STE showed prognostic value in this population and may add to conventional cardiovascular risk factors and other echocardiographic measures. However, our findings also highlight the limitations of the existing evidence base and identify important knowledge gaps in the current literature regarding the possible utility of myocardial deformation indices and 3D-STE in unselected older populations -- these are issues where further evidence is needed.
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Abbreviation list {#S0007}
=================

AF, atrial fibrillation; CHD, coronary heart disease; CVD, cardiovascular disease; DM, diabetes mellitus; GLS, global longitudinal strain; HF, heart failure; LV, left ventricular; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; MI, myocardial infarction; STE, speckle-tracking echocardiography.
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[^1]: **Notes:** ^\*^Studies are from the same cohort (CABL study). ^†^Studies are from the same cohort (Copenhagen City Heart Study).

[^2]: **Abbreviations:** AF, atrial fibrillation; CAD, coronary artery disease; CVD, cardiovascular disease; DM, diabetes mellitus; F/U, follow up; HTN, hypertension; HF, heart failure; Hx, history of; IHD, ischemic heart disease; MI, myocardial infarction; N/A, not reported; PAD, peripheral arterial disease.

[^3]: **Abbreviations:** AF, atrial fibrillation; CV, cardiovascular; CVD, cardiovascular disease; CHD, coronary heart disease; COV, coefficient of variation; GLS, global longitudinal strain; HF, heart failure; ICC, intra-class correlation coefficient; IHD, ischemic heart disease; MI, myocardial infarction; PSI, post-systolic index; PSS, post-systolic shortening; 2D-STE, two-dimensional speckle-tracking echocardiography.

[^4]: **Abbreviations:** AF, atrial fibrillation; BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; ECG, electrocardiogram; GLS, global longitudinal strain; HTN, hypertension; HRs, hazard rations; HR, heart rate; IHD, ischemic heart disease; LAVi, left atrial volume index; LV, left ventricular; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; LVIDd, left ventricular internal dimension in diastole; SBP, systolic blood pressure; SD, standard deviation; TDI, tissue Doppler Imaging.

[^5]: **Abbreviations:** BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; HTN, hypertension; HRs, hazard rations; HR, heart rate; IHD, ischemic heart disease; LA, left atrial; LV, left ventricular; LVEF, left ventricular ejection fraction; LVMi, left ventricular mass index; SBP, systolic blood pressure; SD, standard deviation; TDI, tissue Doppler Imaging.
